Pfizer Inc. (NYSE:PFE) Shares Acquired by Avantax Planning Partners Inc.

Avantax Planning Partners Inc. boosted its position in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 19.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 119,151 shares of the biopharmaceutical company’s stock after purchasing an additional 19,370 shares during the period. Avantax Planning Partners Inc.’s holdings in Pfizer were worth $6,168,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Ullmann Wealth Partners Group LLC grew its holdings in Pfizer by 6.2% during the 1st quarter. Ullmann Wealth Partners Group LLC now owns 5,759 shares of the biopharmaceutical company’s stock worth $298,000 after acquiring an additional 335 shares in the last quarter. Red Door Wealth Management LLC boosted its holdings in shares of Pfizer by 8.6% in the 1st quarter. Red Door Wealth Management LLC now owns 109,620 shares of the biopharmaceutical company’s stock valued at $5,675,000 after buying an additional 8,694 shares during the period. Capital City Trust Co. FL boosted its holdings in shares of Pfizer by 49.9% in the 1st quarter. Capital City Trust Co. FL now owns 8,464 shares of the biopharmaceutical company’s stock valued at $438,000 after buying an additional 2,816 shares during the period. Colonial River Wealth Management LLC boosted its holdings in shares of Pfizer by 52.3% in the 1st quarter. Colonial River Wealth Management LLC now owns 20,988 shares of the biopharmaceutical company’s stock valued at $1,087,000 after buying an additional 7,206 shares during the period. Finally, Annex Advisory Services LLC boosted its holdings in shares of Pfizer by 23.6% in the 1st quarter. Annex Advisory Services LLC now owns 10,279 shares of the biopharmaceutical company’s stock valued at $532,000 after buying an additional 1,966 shares during the period. 66.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Jennifer B. Damico sold 4,218 shares of the business’s stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the sale, the senior vice president now directly owns 10,846 shares in the company, valued at approximately $585,250.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Jennifer B. Damico sold 4,218 shares of Pfizer stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the transaction, the senior vice president now directly owns 10,846 shares of the company’s stock, valued at $585,250.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Jennifer B. Damico sold 4,000 shares of Pfizer stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $50.50, for a total transaction of $202,000.00. Following the completion of the transaction, the senior vice president now directly owns 15,064 shares in the company, valued at $760,732. The disclosure for this sale can be found here. Insiders have sold 41,126 shares of company stock worth $2,075,003 in the last ninety days. 0.05% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on PFE shares. SVB Leerink decreased their price target on shares of Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a report on Friday, July 29th. Morgan Stanley decreased their price target on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a report on Friday, July 8th. Wells Fargo & Company cut their price objective on shares of Pfizer from $60.00 to $55.00 in a research report on Wednesday, May 4th. JPMorgan Chase & Co. set a $57.00 price objective on shares of Pfizer in a research report on Tuesday, June 28th. Finally, Berenberg Bank set a $50.00 price objective on shares of Pfizer in a research report on Friday, May 27th. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Pfizer Price Performance

Shares of PFE stock traded down $0.59 during midday trading on Friday, reaching $49.27. 16,376,601 shares of the company were exchanged, compared to its average volume of 16,878,314. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. The company’s 50 day moving average price is $51.09 and its two-hundred day moving average price is $51.10. Pfizer Inc. has a 12 month low of $40.94 and a 12 month high of $61.71. The company has a market cap of $276.45 billion, a P/E ratio of 9.64, a PEG ratio of 0.61 and a beta of 0.67.

Pfizer (NYSE:PFEGet Rating) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. Pfizer had a net margin of 28.92% and a return on equity of 44.38%. The business had revenue of $27.74 billion for the quarter, compared to the consensus estimate of $26.20 billion. During the same period in the previous year, the firm earned $1.07 EPS. The business’s revenue for the quarter was up 46.8% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 6.54 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Thursday, July 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.25%. Pfizer’s payout ratio is currently 31.31%.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.